Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00474812 · ClinicalTrials.gov registry record · Phase 2
Dasatinib in Treating Patients With Metastatic Pancreatic Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT00474812: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00474812 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 51 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00474812, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well dasatinib works in treating patients with metastatic pancreatic cancer.
Interventions
- DRUG dasatinib
- PROCEDURE laboratory biomarker analysis
- PROCEDURE physiologic testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2007-05 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00474812
The ClinicalTrials.gov registry entry for NCT00474812 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which dasatinib is the first listed.
NCT00474812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00474812 about?
NCT00474812 is a clinical study titled "Dasatinib in Treating Patients With Metastatic Pancreatic Cancer". Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well dasatinib works in treating patients with metastatic pancreatic cancer.
What is the current status of trial NCT00474812?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2007-05. Estimated completion is 2014-02.
What interventions are being tested in trial NCT00474812?
The interventions under investigation include: dasatinib (DRUG), laboratory biomarker analysis (PROCEDURE), physiologic testing (PROCEDURE).
Who is sponsoring clinical trial NCT00474812?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.